NUS

Nu Skin Enterprises' stock price has experienced volatility and declines in the past six months. In Q1 2026, Nu Skin reported earnings that significantly missed analyst expectations, leading to a drop in the stock price. Revenue and field-force contraction were observed, attributed to macroeconomic pressures and disruptions from the company's sales-model transformation. Net income in Q1 2026 dropped significantly, impacted by charges related to winding down the BeautyBio business. For Q2 2026, Nu Skin expects revenue between $330 million and $360 million and EPS between $0.15 and $0.25. The company sold its Mavely platform in 2025 and is investing in its Prysm iO intelligent wellness platform. Nu Skin ended Q1 2026 with $200.4 million in cash and current investments and $225 million of total debt.